Xeltis’ restorative technology at Biomaterials

2019-06-11T12:52:57+00:00April 3rd, 2019|Latest News|

Preclinical data on Xeltis’ restorative heart valves will illustrate supramolecular materials’ potential application in clinical practice at the Society for Biomaterials annual meeting on Thursday 4 April. Xeltis CTO Martijn Cox will present 2-year preclinical data outlining the capability [...]

Xeltis’ RestoreX™ in Cardiovascular Pathology

2019-06-11T12:55:58+00:00March 8th, 2019|Latest News|

Peer-reviewed journal Cardiovascular Pathology published positive one-year in-vivo data on Xeltis’ RestoreX™ technology platform in its latest issue. According to the paper, preclinical results of RestoreX™ pulmonary graft confirmed the potential of Xeltis’ restorative cardiovascular approach. The study showed that [...]

Xeltis’ new leadership functional to next phase

2019-06-11T12:58:38+00:00March 1st, 2019|Latest News|

Mohammed El-Kurdi, PhD, Vice President for Tissue Science, and Luc Verhees, Senior Vice President for Clinical, Pre-clinical and Medical Affairs, joined Acting CEO Eliane Schutte - Xeltis CDO since 2016 - and CTO and Co-founder Martijn Cox on Xeltis’ leadership [...]

Children’s Hospital Los Angeles joins the Xplore-2 Study

2019-02-11T17:27:22+00:00June 22nd, 2018|Latest News|

Children’s Hospital Los Angeles (CHLA) recently joined other prominent U.S. pediatric centers in the Xplore-2 clinical research study. The medical institutions that may enroll patients in the Xplore-2 Early Feasibility Study also include: Boston Children’s Hospital, Children’s Healthcare of [...]

Go to Top